Skip to main content
. 2022 Jan 15;14(1):19–37. doi: 10.4251/wjgo.v14.i1.19

Table 2.

Summary of biomarkers worthy of further development in gastrointestinal tumors

Classification
Biomarkers
Tumor type
Response to ICI
Ref.
Tumor-genome biomarkers POLE-mutation Endometrial carcinoma Pos [93]
Neoantigen Pulmonary adenocarcinoma Pos [94]
Liquid-biopsy biomarkers LDH Melanoma Neg [99]
NLR Advanced solid tumors Neg [100]
Epigenetic TET1-mutation Multiple tumor types Pos [105]
miRNA Non-small-cell lung cancer Pos [107]
Patient characteristic Gender NA Male: Pos; Female: Neg [81,82]
Age NA Controversial1 [84,115]
Intestinal microbiota NA Pos/Neg [85-87]
1

Age as a marker remains controversial, and there are conflicting cases of relevant data.

POLE: Polymerase gene epsilon; LDH: Lactate dehydrogenase; NLR: Neutrophil-to-lymphocyte ratio; miRNA: Micro RNA; Pos positive: Neg negative; NA: Not applicable; ICI: Immune checkpoint inhibitor.